section name header

Pronunciation

EL-a-GOE-lix

Classifications

Therapeutic Classification: analgesics

Pharmacologic Classification: gnrh antagonist

Indications

REMS


Action

  • Competitively binds to and inhibits gonadotropin-releasing hormone receptors in the pituitary gland, causing a decrease in the release of estradiol and progesterone by the ovaries.
Therapeutic effects:

Pharmacokinetics

Absorption: Rapidly absorbed.

Distribution: Unknown.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP3A isoenzyme with some metabolism by the CYP2D6 and CYP2C8 isoenzymes as well as UGT. 90% of dose excreted in feces, <3% in urine.

Half-Life: 4–6 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash

Endo: hot flush, night sweats

GI: nausea, liver enzymes, abdominal pain, constipation, diarrhea

GU: libido, menstrual irregularities

Metab: weight, dyslipidemia

MS: bone density, arthralgia

Neuro: headache, anxiety, depression, dizziness, insomnia, mood swings, SUICIDAL THOUGHTS/BEHAVIOR

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Hepatic Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Orilissa